Kineta Resumes Enrollment Of Anti-VISTA Antibody Trial

 
• By Joseph Haas

An option fee from potential program acquirer TuHura has enabled Kineta to resume enrolling a Phase I/II study of a VISTA-targeted antibody that the company thinks has best-in-class potential.

Immune checkpoint inhibitor
Kineta resumes enrolling a trial for what it hopes will be a novel class of checkpoint inhibitors • Source: Shutterstock

More from Clinical Trials

More from R&D